Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
NCT ID: NCT01198171
Last Updated: 2024-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
243 participants
OBSERVATIONAL
2010-01-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer
NCT01119573
Biomarkers in Samples From Patients With Endometrial Cancer
NCT01199250
Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom
NCT00758056
Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
NCT07062016
Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer
NCT01150682
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To identify racial categorization as the proportion of genetic background of African-American or European-American women with endometrioid endometrial cancer (EEC).
II. To evaluate the association of racial genetic admixture with clinicopathologic variables and outcomes.
SECONDARY OBJECTIVES:
I. To compare the concordance between racial genetic admixture and self-designated race categorization.
OUTLINE: This is a multicenter study. Patients are stratified by race (African-American vs European-American) and disease stage (I vs II vs III vs IV).
DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Basic science (DNA analysis)
DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
Laboratory Biomarker Analysis
Correlative studies
Study of Socioeconomic and Demographic Variables
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laboratory Biomarker Analysis
Correlative studies
Study of Socioeconomic and Demographic Variables
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage I-IV disease regardless of grade
* Underwent surgical staging including hysterectomy, bilateral oophorectomy, washings, and pelvic lymphadenectomy
* Eligible and evaluated on GOG-0210 clinical trial, a Molecular Staging Study in Endometrial Cancer
* Available frozen or formalin-fixed and paraffin-embedded normal tissue that is free of tumor cells and yields sufficient high-quality normal DNA for testing
* Consented their specimens and clinical data to be collected and used in future studies
* Self-declared African-American or Caucasian race
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Gynecologic Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodney Rocconi
Role: PRINCIPAL_INVESTIGATOR
Gynecologic Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2011-02867
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000684547
Identifier Type: -
Identifier Source: secondary_id
GOG-8022
Identifier Type: -
Identifier Source: secondary_id
GOG-8022
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-8022
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-8022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.